Thermometer Icon

SHINGRIX should be refrigerated. DO NOT FREEZE:

Store both the antigen and adjuvant between
2º and 8ºC (36º and 46ºF) before reconstitution (discard if frozen).1

Prescription Medication Bottles Icon

SHINGRIX is supplied as an adjuvant and antigen for reconstitution: The antigen is to be reconstituted only with the accompanying adjuvant suspension. After reconstitution, SHINGRIX should be administered immediately or stored refrigerated between 2° and 8°C (36° and 46°F) and used within 6 hours. Discard reconstituted vaccine if not used within 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen.1

Syringe Injection Needle Icon

SHINGRIX is a recombinant vaccine for intramuscular injection only.1

Calendar Icon

SHINGRIX is administered as a 2-dose series:

The second dose should be administered anytime between 2 and 6 months after the first dose to complete the 2-dose series as directed.1

Notepad Icon

The CDC has issued guidance on the SHINGRIX dosing schedule2,3,†

  • Following the first dose of SHINGRIX, the second dose should be given 2-6 months later
  • If more than 6 months have elapsed since the first dose, administer the second dose as soon as possible. You should not restart the vaccine series
  • However:
    • The efficacy of alternative dosing regimens has not been evaluated
    • Data regarding the safety of alternative regimens are limited
    • Individuals might remain at risk for herpes zoster during a longer than recommended interval between doses 1 and 2


SHINGRIX Prescription from Doctor


  View reconstitution instructions for SHINGRIX.

In a phase 3 clinical study designed to help establish the dosing interval for SHINGRIX, all primary endpoints were met for dosing at a 0- and 6-month interval when compared to dosing at a 0- and 2-month interval. However, a co-primary endpoint (noninferiority) of the immune response was missed for dosing at a 0- and 12-month interval. (The upper limit of the 97.5% confidence interval was 1.53, above the predefined limit of <1.5.)4 GSK has not studied the safety or immune response of 3 doses of SHINGRIX in the indicated population (patients ≥50 years of age).1
CDC=Centers for Disease Control and Prevention.


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

References: 1. Prescribing Information for SHINGRIX. 2. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 3. Centers for Disease Control and Prevention. Frequently Asked Questions About Shingrix. Updated August 22, 2018. Accessed September 11, 2018. 4. Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148-154.

All trademarks are the property of their respective owners.

1009726R0 September 2018